The effect of SMN gene dosage on ALS risk and disease severity by Moisse, M. et al.
This is a repository copy of The effect of SMN gene dosage on ALS risk and disease 
severity.




Moisse, M., Zwamborn, R.A.J., Vugt, J. et al. (33 more authors) (2021) The effect of SMN 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE
The Effect of SMN Gene Dosage on ALS
Risk and Disease Severity
Matthieu Moisse, PhD ,1,2 Ramona A. J. Zwamborn, MSc,3 Joke van Vugt, PhD ,3
Rick van der Spek, MD ,3 Wouter van Rheenen, PhD ,3 Brendan Kenna, PhD,3
Kristel Van Eijk, PhD,3 Kevin Kenna, PhD,3 Philippe Corcia, MD ,4,5
Philippe Couratier, MD ,4 Patrick Vourc’h, PhD ,5 Orla Hardiman, MD ,6
Russell McLaughin, PhD ,7 Marc Gotkine, MBBS ,8 Vivian Drory, MD,9 Nicola Ticozzi, MD
,10,11 Vincenzo Silani, MD ,10,11 Mamede de Carvalho, MD ,12
Jesús S. Mora Pardina, MD ,13 Monica Povedano, MD,14 Peter M. Andersen, MD ,15
Markus Weber, MD,16 Nazli A. Başak, PhD ,17 Xiao Chen, PhD ,18
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Objective: The role of the survival of motor neuron (SMN) gene in amyotrophic lateral sclerosis (ALS) is unclear, with
several conflicting reports. A decisive result on this topic is needed, given that treatment options are available now for
SMN deficiency.
Methods: In this largest multicenter case control study to evaluate the effect of SMN1 and SMN2 copy numbers in
ALS, we used whole genome sequencing data from Project MinE data freeze 2. SMN copy numbers of 6,375 patients
with ALS and 2,412 controls were called from whole genome sequencing data, and the reliability of the calls was tested
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with multiplex ligation-dependent probe amplification data.
Results: The copy number distribution of SMN1 and SMN2 between cases and controls did not show any statistical dif-
ferences (binomial multivariate logistic regression SMN1 p = 0.54 and SMN2 p = 0.49). In addition, the copy number
of SMN did not associate with patient survival (Royston-Parmar; SMN1 p = 0.78 and SMN2 p = 0.23) or age at onset
(Royston-Parmar; SMN1 p = 0.75 and SMN2 p = 0.63).
Interpretation: In our well-powered study, there was no association of SMN1 or SMN2 copy numbers with the risk of
ALS or ALS disease severity. This suggests that changing SMN protein levels in the physiological range may not modify
ALS disease course. This is an important finding in the light of emerging therapies targeted at SMN deficiencies.
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Amyotrophic lateral sclerosis (ALS) and spinal muscu-lar atrophy (SMA) are both motor neuron disorders
leading to progressive muscle weakness and death of
patients, mostly due to respiratory failure.1,2
ALS is an adult-onset disease with an estimated life-
time risk of 1 in 400. Approximately 50% of patients die
within 3 to 5 years after onset, but there is a high level of
variability between patients in age at onset and progression
rate, with 5% of the patients surviving more than
10 years.3,4 Patients are typically categorized into familial
ALS representing 10 to 20% of patients and sporadic
ALS. Genetically,  66% of familial and  10% sporadic
patients are explained by a mutation in one of the  25
genes that have been associated with ALS, with mutations
in SOD1, TARDBP, FUS, and C9orf72 being the most
common causes.1 To date, several clinical and genetic fac-
tors have been put forward as disease modifiers, for exam-
ple, sex, age at onset, site of onset, diagnostic delay,
presence of frontotemporal dementia, C9orf72 repeat
expansions and SNPs in or near UNC13A, and
CAMTA1.5 In addition, copy number (CN) variation in
SMN, the gene that is deleted in childhood onset SMA,
has been extensively studied as disease modifier with many
conflicting reports.6–15
SMA is a monogenic disease usually caused by a
homozygous loss of SMN1 and modulated by the number
of SMN2 copies present.16 In  95% of the cases, both
copies of SMN1 are missing or affected by a gene conver-
sion, the remaining  5% of the patients have a mutation
on their remaining copy of SMN1.17 The SMN genes are
located on q13.2 of chromosome 5, a locus that under-
went an inverted duplication of about 500 kb.18 SMN2 is
almost identical to SMN1, except for a few point muta-
tions and small insertions and deletions, one of which is
located at the splice junction of exon 7 and causes exon
7 skipping.18 As a consequence, SMN2 mainly codes for a
non-fully functional SMN protein.16 Recently, 3 treatment
options became available that aim to increase full length
functional SMN protein levels. The first one is a multi-
dose antisense oligonucleotide therapy named nusinersen,
the second is the single dose gene replacement therapy
onasemnogene abeparvovec, and the third option is
experimental compound therapies, aiming to increase the
expression of the SMN locus.19,20 Nusinersen works
through blocking the binding of heterogeneous nuclear
ribonucleoproteins (hnRNPs) at a splicing silencer ele-
ment, named ISS-N1, leading to exon 7 inclusion and
increases full length SMN protein levels.2,19
Onasemnogene abeparvovec adds a functional copy of
SMN1 to the genome using a self-complementary adeno-
associated viral serotype 9, increasing the SMN protein
levels.20
These recent therapeutic breakthroughs in SMA
could have large consequences for ALS as well, if a con-
vincing role for SMN in ALS could be established.
Previous studies investigating the effect of the CNs
of SMN on disease risk and progression of ALS have
reported conflicting results.6–15 According to some studies,
loss of SMN1 is associated with ALS risk,8,9,12 whereas
others found that duplication of SMN1 associated with
ALS risks.6,7,11–13 Others did not find any association
between ALS and the number of SMN1 copies.10,14,15
Likewise for SMN2, some found a homozygous deletion
to be protective,8 whereas others found the deletion to be
more frequent in ALS and reducing the survival time of
these patients.9,10,15 In addition, here, several other publi-
cations failed to find any association.6,7,11–14
In this large study, we aimed to use the whole
genome sequencing (WGS) data from Project MinE,
which contains 6,375 patients with ALS and 2,412 con-
trols to evaluate the effect of SMN CNs in the context of
ALS risk and clinical phenotype.21 This is the largest ALS
cohort in which SMN genes have been analyzed in the
hope to find a definitive answer.
Methods
Experimental Design
This WGS case–control study uses data freeze 2 from Pro-
ject MinE, which contains a total of 9,600 whole genomes
sequencing data from ALS cases and age-matched and sex-
matched control samples.21 Samples were mostly of people
of European descent and collected from 17 centers across
13 countries: Belgium, Switzerland, Spain, France, United
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Kingdom, Ireland, Israel, Italy, The Netherlands, Portu-
gal, Sweden, Turkey, and the United States.
Patients were diagnosed with ALS in their respective
centers, mainly using the El-Escorial criteria. Clinical
information was collected from each center and centrally
harmonized and passed though quality control. For
patients who are still alive, a survival update was requested
on a yearly basis. All participants signed an informed con-
sent at their respective centers. This study was approved
by the respective ethics committees of the participating
centers.
Sequencing, Variant Calling, and Quality Control
The first batch of 2,250 cases and control samples were
sequenced on the Illumina HiSeq 2000 platform. All
remaining 7,350 cases and controls were sequenced on the
Illumina HiSeq X platform. All samples were sequenced
to  35X coverage with 100 bp reads and  25X cover-
age with 150 bp reads for the HiSeq 2000 and HiSeq X,
respectively. Both sequencing sets used polymerase chain
reaction (PCR)-free library preparation. Samples were also
genotyped on the Illumina 2.5 M array. Sequencing data
were then aligned to GRCh37 using the iSAAC Aligner,
and variants called using the iSAAC variant caller; both
the aligner and caller are standard to Illumina’s aligning
and calling pipeline.
Per individual, gVCFs were merged using the
Illumina gvcfgenotyper tool version 2018.10.15 (https://
github.com/Illumina/gvcfgenotyper). Sites with a geno-
type quality (GQ) < 10 were set to missing and single
nucleotide variations (SNVs) and indels with quality
(QUAL) scores < 20 and < 30, respectively, were
removed. Biological sex was inferred from the average cov-
erage of chrY and chrX compared with the average cover-
age of the autosomal chromosomes.
Next sample-level quality control was performed
using the following filters at sample level: (1) more than
2% of the variant missing, (2) abnormal value of the auto-
somal homozygous genotype score calculated by Plink 1.9
jFj > 0.10, (3) aberrant transition/transversion ratio,
defined as ±6 standard deviations (SDs), (4) aberrant
number of variants, defined as ±6 SDs, (5) aberrant num-
ber of singletons, defined as ±6 SDs, (6) aberrant number
of indels, defined as ±6 SDs, and (7) an inconsistency
between the inferred and reported sex.
Variants in the merged vcf file were first decomposed
and normalized using the corresponding commands in vt
(version 2015.11.10) and then annotated by VEP (version
96), information from public databases dbNSFP (version
3.5a), dbscSNV (version 1.1), ExAC (version 0.3),
gnomAD exome (version 2.1), ESP (ESP6500SI-V2),
1,000 genomes (phase 3), dbsnp (version 151), and
clinvar (version 20190513) were added using vcfanno
(version 0.3.1). Annotated vcf files were loaded into gem-
ini (version 0.30.1) and filtered for exonic variants,
excluding synonymous variants not near splice sites, with
an allele frequency of maximum 2%. Resulting variants in
SOD1, FUS, and TARDBP were further inspected using
the ACMG guidelines on the varsome platform.22 Patho-
genic, likely pathogenic, and variants of unknown signifi-
cance with some evidence toward pathogenicity were
retained for further analysis. C9ORF72 expansions were
detected using Expansion Hunter (version 3.1.2) from
Illumina.23
SMN Calling
To call the CNs of SMN from WGS data we used the
recently published SMNCopyNumberCaller (SMNCNC)
tool from Illumina.24 In brief, this method uses read
depth information at the 8 loci in the SMN1 and SMN2
genes to determine the consensus CN of both genes (coor-
dinates against hg19): site number 7 (intron 6, SMN1
chr5-70246320-G, SMN2 chr5-69370895-A), site num-
ber 8 (intron 6, SMN1 chr5-70246793-G, SMN2 chr5-
69371368-A), site number 10 (intron 6, SMN1 chr5-
70247219-G, SMN2 chr5-69371799-A), site number 11
(intron 6, SMN1 chr5-70247290-T, SMN2 chr5-
69371870-C), site number 12 (intron 6, SMN1 chr5-
70247724-G, SMN2 chr5-69372304-A), site number 13
(Splice site variant in exon 7, SMN1 chr5-70247773-C,
SMN2 chr5-69372353-T), site number 14 (intron7,
SMN1 chr5-70247921-A, SMN2 chr5-69372501-G),
and site number 15 (intron7, SMN1 chr5-70248036-A,
SMN2 chr5-69372616-G). Wet lab validation was per-
formed using multiplexed ligation-dependent probe ampli-
fication (MLPA) using standard protocols as described by
Blauw et al.7
Power Analysis
Power calculations were performed for the survival and
onset analysis using the powerCT function of the R pack-
age powerSurvEpi (version 0.1.0), with a p value threshold
of 0.05.
Statistical Analysis
To test the independence of the SMN CN distributions
between cohorts we used a 2-sided asymptotic generalized
Pearson Chi-Squared test (gχ2) provided by the chisq_test
method of the R package coin (version 1.3–1), with SMN
CN as ordinal and cohort as nominal. When comparing
the SMN CN distribution of only two cohorts a 2-sided
asymptotic linear-by-linear (lbl) association test was used,
implemented by the same chisq_test method.
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For the corrected risk analysis, a 2-sided binomial
multivariate logistic regression was performed using the
glm function from the R stats package. SMN CN was
added to the model as a categorical variable with baseline
a CN of 2, while correcting for the following terms: sex,
sequencing technology, cohort, the first 20 HapMap pro-
jected principal components (PCs), and the mutation sta-
tus of C9orf72, SOD1, FUS, and TARDBP.
Cox survival analysis was performed using the coxph
function of the R package survival (version 3.1–8). Flexible
survival regression using the Royston-Parmar (RP) spline
model was performed using the flexsurvspline function from
the R package flexsurv (version 1.1.1). When assessing the
effect of SMN CN on survival SMN CN was treated as a cat-
egorical variable with baseline a CN of 2. Survival analyses
were corrected for age at onset, sex, site of onset, C9orf72
expansion status, sequencing technology, cohort, and the first
20 HapMap projected PCs. Onset analyses were corrected
for sex, sequencing technology, cohort, and the first
20 HapMap projected PCs.
Meta-analysis of the individual cohort was per-
formed using the meta (version 4.13–0) and metafor (ver-
sion 2.4–0) R packages. The same covariates were used as
in the risk, survival, and onset analysis, but only the first
5 HapMap projected PCs were used.
Results
Validating SMN Calls from WGS Data
We used 2,412 controls and 6,375 cases that passed the
QC metric and had sufficient clinical information (Table
and Table S1). For these samples, we ran SMNCNC to
estimate the CN of SMN1 and SMN2. For 475 of our
samples, we also had SMN CNs available from MLPA.
We excluded samples where the MLPA results for exon
7 and exon 8 disagreed with each other. The concordance
between the MLPA results of exon 7 and exon 8 was
89.3% for SMN1 and 97.9% for SMN2. Excluding dis-
cordant samples resulted in a set of 413 samples. This set
was then further compared with the results of SMNCNC,
with a concordance of 99.3% and 99.5% for SMN1 and
SMN2, respectively, which is similar to previous findings
(Figs 1 and 2).24
SMN CNs as a Risk Factor for ALS
To investigate if our SMN CN estimates can be used in a
risk factor analysis, we first compared the frequency of
SMN copies in our controls to published literature
(Fig 3A, B, and Table S2).7,12,25–27 To assess the CN dis-
tributions across multiple groups we used a gχ2 test,
whereas we used the lbl test when comparing the distribu-
tion between the 2 groups. Assessing the SMN1 and
SMN2 CN distribution across the different control
populations revealed geographic differences, as previously
reported (SMN1; gχ2 p < 2.2 × 10-16; SMN2 gχ2
p = 5.1 × 10-7).27 When comparing our SMN1 CN distri-
bution to a Caucasian population of 2,175 individuals we
did not find any difference (lbl p = 0.16; see Fig 3A), con-
firming that our control population is representative.27
Within the control samples of Project MinE no difference
in SMN1 or SMN2 CN frequency was observed between
TABLE. Phenotype Information of the MinE Participants
Project MinE
ALS (%) Control (%)
6375 (72.55) 2412 (27.45)
Sex
Male 3,815 (59.84) 1,272 (52.74)
C9orf72 status







ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia.
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FIGURE 1: Raw data plots for discordant MLPA call. MPLA called 3 CNs for SMN1 in sample LP6008185-DNA_A08, whereas
SMNCNC called 4 CNs for SMN1. Closer inspection revealed SMNCNC to be correct. (A) Raw CN of full length SMN1 estimated by
exon 7 and 8, histogram indicating the estimated CN of a large control cohort, vertical blue line indicates the discordant sample.
(B) SMN1 and SMN2 raw CN values at the 8 loci used to determine the consensus CN. (C) SMN1 and SMN2 CNs normalized against
coverage depth at 8 the loci. (D) Scatterplot of the raw CN calls by MLPA, on the x-axis raw CN for SMN1, on the y-axis raw CN for
SMN2, discordant sample indicated with a line. (E) Scatter plot of the raw CN calls by SMNCNC, on the x-axis raw CN for SMN1, and
on the y-axis raw CN for SMN2, discordant sample indicated with a line. CN = copy number; MLPA = multiplexed ligation-dependent
probe amplification; SMN = survival of motor neuron; SMNCNC = SMNCopyNumberCaller; WGS = whole genome sequencing.
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the cohorts (SMN1; gχ2 p = 0.45; SMN2; gχ2 p = 0.53;
Fig 4 and Tables S3 and S4).
When looking at SMN CN frequency in patients
with ALS of published cohorts and our own we do
observe a significant difference for SMN1 CN (gχ2
p = 7.3 × 10-4) but not for SMN2 CN (gχ2 p = 0.10).
Within Project MinE no differences between cohorts for
SMN1 CN (gχ2 p = 0.52) were observed, whereas for
SMN2 differences were observed (gχ2 p = 4.9 × 10-4), in
the Turkish cohort (see Fig 4B and Tables S3 and S4).
Comparing SMN1 frequency between cases and
controls within Project MinE revealed no significant dif-
ferences (lbl p = 0.54), similarly SMN2 also did not show
any differences (lbl p = 0.23; see Fig 3C, D). Using a
binomial logistic regression, we performed a corrected case
control risk analysis for the SMN CN. Similarly, we did
not observe any significant differences for the SMN CN
status between cases and controls (binomial multivariate
logistic regression; SMN1 p = 0.54 and SMN2 p = 0.49).
Cohort analysis within Project MinE and meta-analysis of
the cohorts did not reveal any differences (see Fig 4). In
addition, other CN categories, including duplications of
SMN1 or SMN2 (lbl; SMN1 p = 0.55 and SMN2
p = 0.71; binomial multivariate logistic regression; SMN1
p = 0.73 and SMN2 p = 0.83) or deletions (lbl; SMN1
p = 0.69 and SMN2 p = 0.22; binomial multivariate logis-
tic regression; SMN1 p = 0.98 and SMN2 p = 0.39) did
not associate with ALS.
SMN CNs as a Modifier for ALS
As the CN of SMN has been proposed as a disease modi-
fier, we also investigated the effect on age at onset and sur-
vival.10,15 For this, we performed both a Cox regression
and a RP analysis,28 while correcting for covariates. This
revealed no significant association with survival for SMN1
(Cox hazard ratio [HR] = 1.00, 95% confidence interval
[CI] = 0.91–1.11, p = 0.89; RP HR = 0.98, 95%
CI = 0.84–1.14, p = 0.78) or SMN2 (Cox HR = 1.01,
95% CI = 0.97–1.05, p = 0.67; RP HR = 1.04, 95%
CI = 0.97–1.12, p = 0.23; Fig 5A, B). Meta analyzing the
results in the individual cohorts with a random effect
model revealed no significant associations for SMN1 (Cox
HR = 1.00, 95% CI = 0.90–1.10, p = 0.96; RP
HR = 0.95, 95% CI = 0.80–1.13, p = 0.59) or SMN2
(cox HR = 1.01, 95% CI = 0.95–1.07, p = 0.73; RP
HR = 1.04, 95% CI = 0.95–1.13, p = 0.43). Power analy-
sis showed that our cohort had an 80% power to detect a
25% change in expected hazard for SMN1 deletion
( 9 months), 16% for SMN1 duplication ( 6 months),
9% for SMN2 deletion ( 3 months), and 22% for
SMN2 duplications ( 9 months).
Similarly, we investigated the effect on onset, while
correcting for covariates. Neither SMN1 nor SMN2
showed a significant association with onset at the level of
the whole cohort (SMN1; Cox HR = 0.98, 95%
CI = 0.90–1.06, p = 0.63, RP HR = 0.98, 95%
CI = 0.85–1.13, p = 0.75; SMN2; Cox HR = 1.00, 95%
CI = 0.97–1.04, p = 0.86, RP HR = 1.01, 95%
CI = 0.95–1.08, p = 0.63) or by the cohort analysis (see
Fig 5C, D). Likewise, meta analyzing using a random
effect model revealed no significant associations for SMN1
(Cox HR = 0.97, 95% CI = 0.89–1.06, p = 0.49; RP
HR = 0.94, 95% CI = 0.75–1.17, p = 0.57) or SMN2
(Cox HR = 1.00, 95% CI = 0.94–1.07, p = 0.85; RP
HR = 1.01, 95% CI = 0.91–1.13, p = 0.83). Power analy-
sis for the age at onset analysis showed we had an 80%
power to detect a 21% change in expected hazard for
SMN1 deletion, 14% for SMN1 duplication, 7% for
SMN2 deletion, and 19% for SMN2 duplications.
Discussion
Our study, in a large cohort of patients with ALS for
which SMN1 and SMN2 CNs have been assessed, shows
that no association can be found between the CN of the
SMN genes and ALS risk or disease severity. This is in line
with some previously published studies, but inevitably also
contradicts some previous findings in much smaller
studies.6–15 Given that our study is currently by far the
largest available, includes samples spread out over a wide
range of geographical areas, is well powered, and subgroup
analyses did not reveal any associations, this study pro-
vides conclusive evidence that SMN genes do not have a
role in ALS pathogenesis through SMN gene
CN. Previous studies reported an increased risk of ALS up
to 2-fold to 5-fold for carriers with only one copy of
SMN1, which represent carrier status of SMA.9,12,13 Our
study clearly shows that SMA carriers, representing  2%
of the population, are not at an increased risk of develop-
ing ALS. The CN distribution in our control samples
were consistent with an independent large control cohort,
further validating our approach.27
WGS data identify a multitude of genomic varia-
tions, including single point variants, small insertions,
deletions, and structural variations. Additionally, an
increasing amount of reliable bioinformatic tools become
available for WGS data to assess complex genomic regions
like, for example, repeat expansions or genomic duplica-
tions like the SMN region, allowing to extract new infor-
mation from WGS data with unprecedented ease and
speed, without the necessity of additional wet lab experi-
ments. A recent study evaluating the reliability of wet lab
testing of the C9orf72 repeat across multiple laboratories,
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FIGURE 2: Raw data plots for discordant SMNCNC call. MPLA called 3 CNs for SMN1 in sample LP6005947-DNA_D01, whereas
SMNCNC called 2 CNs for SMN1. Closer inspection revealed MLPA to be correct. (A) Raw CN of full length SMN1 estimated by exon
7 and 8, histogram indicating the estimated CN of a large control cohort, vertical blue line indicates the discordant sample. (B) SMN1
and SMN2 raw CN values at the 8 loci used to determine the consensus CN. (C) SMN1 and SMN2 CN normalized against coverage
depth at the 8 loci. (D) Scatterplot of the raw CN calls by MLPA, on the x-axis raw CN for SMN1, and on the y-axis raw CN for SMN2,
discordant sample indicated with a line. (E) Scatter plot of the raw CN calls by SMNCNC, on the x-axis raw CN for SMN1, and on the
y-axis raw CN for SMN2, discordant sample indicated with a line. CN = copy number; MLPA = multiplexed ligation-dependent probe
amplification; SMN = survival of motor neuron; SMNCNC = SMNCopyNumberCaller; WGS = whole genome sequencing.
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showed a low concordance between different laboratories,
highlighting the difficulties of wet lab testing and accom-
panying result interpretations.29 It has recently been
shown that C9orf72 calls made from WGS data were
more reliable than their wet lab counterparts.23 The power
of WGS is that it offers a one-stop solution for all the
known genetically relevant ALS information, including
genetic variation in complex regions.
Recently, SMA became a treatable disease currently
with 3 treatment options. The first option is the use of
chronic intrathecal antisense oligonucleotide therapy, that
aims to convert SMN2 gene products that lack exon 7 into
full length SMN1 protein.19 The second option is a single
dose viral gene replacement therapy that adds an extra
copy of SMN1 into the patient’s genome.20 In addition,
compound therapies are being developed to increase the
expression of the SMN locus. These breakthroughs in
SMA could be important for ALS as well. The SMN1
protein plays important roles in RNA metabolism, which
has been implicated in ALS as well. However, the motor
neuron death cascades seem to be distinct in both dis-
eases.30,31 Given our findings and the differences at
genetic and molecular level that led to motor neuron
death in ALS and SMA, current SMA treatment options
may not be beneficial for patients with ALS.
Although our genetic findings show that SMN CN
is not involved in ALS, it does not entirely rule out that
changes in protein levels contribute to motor neuron
degeneration in ALS. SMN protein levels are not solely
determined by the CN state of the SMN genes, many pro-
cesses influence protein level, including mRNA transcrip-
tion, translation efficiency, post translational modification,
and protein aggregation and sequestration. CN levels of
SMN1 and SMN2 correlate with mRNA levels in blood,
spinal cord, and cerebellum, as previously shown.32,33 Pro-
tein levels do so to a lesser extent in blood and cerebel-
lum, and not in the spinal cord.32,34 Taken together these
(Figure legend continues on next page.)
FIGURE 3: Frequency of the CNs of the SMN1 and 2 genes.
Frequency of (A) SMN1 and (B) SMN2 copy number in
control individuals of this study (MinE), Feng Y. et al. (White,
Hispanic, Ashkenazi Jewish, Asian, and African American),
Blauw HM. et al. (The Netherlands), Corcia P. et al. (France),
Yoon S. et al. (Korea), and Fang P. et al. (China).
Comparisons of the different cohort toward this study for
SMN1 (lbl p value): White (0.16), Netherlands (3.2 × 10-3),
France (1.3 × 10-3), Hispanic (3.4 × 10-5), Ashkenazi Jewish
(0.20), Asian (0.83), Korea (0.07), China (0.25), and African
American (<1 × 10-16); and SMN2: Netherlands (1.1 × 10-2),
France (0.63), Korea (2.3 × 10-4), and China (7.6 × 10-6).
Frequency of (C) SMN1 and (D) SMN2 copy numbers in
patients with ALS and control individuals in this study. ALS =
amyotrophic lateral sclerosis; CN = copy number; lbl = linear-
by-linear.
8 Volume 00, No. 0
ANNALS of Neurology
results show protein levels cannot be reliably predicted on
SMN CN state alone. Furthermore, our findings do not
rule out that overexpression of SMN to levels above the
physiological range can have beneficial effects in protecting
motor neurons in ALS. Indeed, previous work showed
that motor neurons with the same genetic background dis-
play a wide heterogeneity of SMN expression and that
mostly the motor neurons with a low level of SMN are
vulnerable for motor neuron death.35 Additionally, they
showed that using compounds that increase SMN protein
levels, through SMN1 expression promotion, but not
SMN2, were beneficial for the survival of motor neurons,
not only in SMA but also in an ALS context and in
healthy controls.35
This study has some limitations. Project MinE is
not a population-based study, but a multicenter study in
which data and samples from different centers and coun-
tries are included. Samples are mostly from people of
European descent. This could potentially limit the exter-
nal validity to a wider, more diverse population and lead
to population stratification. However, Project MinE
explicitly aims to include balanced case control cohorts
resulting in control samples not being significantly differ-
ent from previously published data sets.21 This, together
with the large sample size and multivariate analyses,
therefore add to the credibility of these results. Last, given
the complexity of the SMN locus, we did not investigate
the role of point mutations and small indel in the SMN
genes in the context of ALS, as these mutations could also
lead to a loss-of-function, like SMN1 gene deletions. In
the light of our current results and the fact that they rep-
resent only 5% of SMN1 mutations, chances are small
that these do play a role in ALS.17
In summary, in our well-powered study, using
highly reliable and validated SMN calls, there was no asso-
ciation of SMN1 or SMN2 CNs with the risk of ALS or
ALS disease severity. This suggests that changing SMN
expression levels in the physiological range may not mod-
ify the progression of ALS. This is an important finding
in the light of emerging therapies targeted at SMN
deficiencies.
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